Novo Nordisk (NVO) Stock Price Prediction: BMO’s higher target meets a mixed technical tape

BMO lifts its target, but not the rating

BMO Capital Markets raised Novo Nordisk (NVO) from $40 to $44 and kept a Market Perform rating, citing strong Wegovy pill performance and U.S. sales 17% above consensus, according to the November 5, 2026 report. That matters because it gives NVO stock a higher referenced upside level from a named analyst house, but the unchanged rating signals the firm is not turning overtly bullish.

For traders, the key takeaway is that the fundamental read-through is supportive, but not enough to erase the market’s need for confirmation from price and volume.

Price action is constructive, but the stock is pressing into resistance

NVO is quoted at $41.30, up 1.03% on the day, after moving in a $40.20 to $41.58 24-hour range. The short- and medium-term trend structure is still positive: SMA 7 at $40.77, SMA 20 at $40.02, and SMA 50 at $39.09, with the faster averages stacked above the slower ones. That is a clean bullish alignment.

The catch is location. NVO is sitting above the pivot point at $41.03 and near the immediate resistance at $41.85, with strong resistance at $42.41. The Bollinger setup says the same thing in different language: the upper band is $42.01, and the %B reading of 0.8214 puts the stock near the upper band rather than in a deep breakout state. In plain terms, the trend is up, but the tape is not cheap.

Momentum is positive, but not cleanly accelerating

The momentum picture is mixed rather than euphoric. RSI at 58.36 sits in neutral-to-positive territory, which supports the uptrend without flashing an overbought signal. Stochastic %K at 54.57 and %D at 43.65 also point to a market that is firm but not stretched.

MACD is less compelling. The MACD, signal, and histogram are all flat at 0.4811 / 0.4811 / 0.0000, which removes immediate downside momentum but also suggests the latest move lacks strong acceleration. Combined with the ATR(14) of $1.24, NVO can still move decisively in either direction if volume expands, but the current tape does not yet show that expansion.

Derivatives lean long, but the confirmation is weak

Binance perpetual futures data show a mildly crowded long bias rather than a clean squeeze setup. The global long/short ratio is 2.3921, with 70.5% long and 29.5% short, while top-trader accounts are even more tilted at 3.2882, or 76.7% long and 23.3% short, as of November 12, 2026. Funding is neutral at 0.0000%, so longs are not paying up aggressively to hold exposure.

That said, the derivatives tape is not fully supportive. Open interest is 23,566.60 contracts, with OI value of $908,142 and a 24-hour OI decline of 4.39%. At the same time, the taker buy/sell ratio is 0.6148, with 79 buy volume versus 129 sell volume, which points to aggressive selling pressure even as positioning remains net long. That combination usually means the market is carrying long exposure, but recent order flow has been leaning against it.

What has to hold for the bullish case

The bull case is straightforward: NVO needs to stay above the $41.03 pivot and defend $40.47 immediate support. If it does, the next test is $41.85, then $42.01 to $42.41 where both the upper Bollinger band and strong resistance sit. A clean break through that zone would improve the argument that the current bounce is becoming a more durable move rather than just a rebound inside a range.

If price loses $40.47, the next line is $39.65 strong support. That level matters because it would put the stock back below the bullish near-term structure and closer to the lower end of the recent range. The trend would not be broken immediately, but the character of the move would shift from controlled pullback to failed breakout.

Trading read

NVO stock looks technically constructive, with the moving-average stack and price location still favoring the upside. But the move is not being confirmed by volume, open interest is slipping, and taker flow is leaning sell-side. That leaves Novo Nordisk (NVO) in a classic “good trend, imperfect confirmation” setup: positive enough to respect, but close enough to resistance that follow-through still has to prove itself.